Bridges Investment Management Inc. Makes New $213,000 Investment in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bridges Investment Management Inc. bought a new position in Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,726 shares of the company’s stock, valued at approximately $213,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kestra Investment Management LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth about $27,000. Huntington National Bank raised its stake in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after buying an additional 181 shares during the period. International Assets Investment Management LLC raised its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after buying an additional 1,138 shares during the period. Covestor Ltd raised its stake in shares of Prestige Consumer Healthcare by 95.6% in the third quarter. Covestor Ltd now owns 1,338 shares of the company’s stock worth $96,000 after buying an additional 654 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock worth $108,000 after buying an additional 220 shares during the period. 99.95% of the stock is owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Stock Up 0.7 %

Shares of PBH opened at $85.34 on Tuesday. The business’s 50 day moving average is $80.18 and its 200 day moving average is $77.40. The company has a market capitalization of $4.23 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.69 and a beta of 0.50. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $88.36. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on PBH. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. DA Davidson raised their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Oppenheimer raised their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $92.60.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.